Depends on the parameters of the software you're using so we're probably both correct. I'm looking at the TD Am daily, one month chart which shows June 29.
IMO I like what I'm seeing from an investor's perspective. The short term traders have exited but no Tutes have sold a share since Sabby bailed in mid-May. Fintel shows 23 Tutes holding 63% of BPMX shares.
The short sellers have also backed off. The average FINRA daily shorting for July is 37% which is low (Bullish IMO) for BPMX or any spec biotech for that matter.
BBs are starting to squeeze & we're waiting on News. The BPX-01 open label P2 Rosacea trial estimated primary completion date is August 2017. Will BPMX find a partner or will they dilute? IMO, BPX-01 is only the beginning, the BPMX solubilized gel product "vehicle" is the Blockbuster that Big Pharma is targeting.
I'm not trading BPMX, am in it for the long haul. These 12 week clinical trials are "fast" so it's easy to be long-term here IMHO. Any negative effects from possible dilution will be short lived buying opportunities. Then again, BPMX could find a partner...
GLTL
